BioMarin Pharmaceutical has secured FDA approval for its supplemental Biologics License Application (sBLA) for Palynziq, expanding its use to adolescents aged 12 years and above diagnosed with phenylketonuria (PKU). This approval marks a significant milestone in the treatment landscape for PKU, a rare genetic disorder that can lead to serious neurological issues if left untreated.
The inclusion of adolescents in the approved indication reflects an evolving understanding of PKU management, recognizing the need for effective therapies during critical developmental stages. With Palynziq now available for this younger demographic, healthcare providers can offer a targeted treatment option that addresses the unique challenges faced by adolescents with PKU.
This development not only enhances BioMarin’s portfolio but also underscores the growing emphasis on personalized medicine in the pharmaceutical industry. As companies continue to innovate in rare disease treatments, the approval may pave the way for further advancements and regulatory approvals in similar therapeutic areas.
Use the database as your supply chain compass →
